Compare Stocks: ACRV, SABS, UPB, and IFRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.70	$1.88	$1.27 ▼ $3.56	$72.85M	1.92	261,314 shs	463,728 shs
IFRX InflaRx	$2.06 +1.0%	$2.00	$0.80 ▼ $2.95	$300.63M	2.52	779,410 shs	657,857 shs
SABS SAB Biotherapeutics	$3.50 +3.2%	$3.66	$1.85 ▼ $5.15	$308.44M	0.53	275,485 shs	374,463 shs
UPB Upstream Bio	$5.31 -0.4%	$6.63	$5.24 ▼ $33.68	$291.93M	1.28	568,381 shs	533,871 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-7.10%	-14.57%	-17.07%	+8.28%	+9.68%
IFRX InflaRx	+0.99%	-2.39%	-1.45%	+13.02%	+78.95%
SABS SAB Biotherapeutics	-0.59%	-2.59%	-10.08%	-15.25%	+57.67%
UPB Upstream Bio	-2.74%	-10.57%	-25.35%	-14.72%	-69.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.70	$1.88	$1.27 ▼ $3.56	$72.85M	1.92	261,314 shs	463,728 shs
IFRX InflaRx	$2.06 +1.0%	$2.00	$0.80 ▼ $2.95	$300.63M	2.52	779,410 shs	657,857 shs
SABS SAB Biotherapeutics	$3.50 +3.2%	$3.66	$1.85 ▼ $5.15	$308.44M	0.53	275,485 shs	374,463 shs
UPB Upstream Bio	$5.31 -0.4%	$6.63	$5.24 ▼ $33.68	$291.93M	1.28	568,381 shs	533,871 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-7.10%	-14.57%	-17.07%	+8.28%	+9.68%
IFRX InflaRx	+0.99%	-2.39%	-1.45%	+13.02%	+78.95%
SABS SAB Biotherapeutics	-0.59%	-2.59%	-10.08%	-15.25%	+57.67%
UPB Upstream Bio	-2.74%	-10.57%	-25.35%	-14.72%	-69.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	694.12% Upside
IFRX InflaRx	2.67	Moderate Buy	$7.43	260.61% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	242.86% Upside
UPB Upstream Bio	2.43	Hold	$29.67	458.69% Upside

Current Analyst Ratings Breakdown

Latest ACRV, SABS, UPB, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
IFRX InflaRx	$30K	10,119.41	N/A	N/A	$0.65 per share	3.17
SABS SAB Biotherapeutics	$1.32M	241.26	$0.35 per share	9.92	$3.18 per share	1.10
UPB Upstream Bio	$2.85M	102.05	N/A	N/A	$6.29 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest ACRV, SABS, UPB, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
IFRX InflaRx	N/A	8.22	8.22
SABS SAB Biotherapeutics	0.01	9.22	9.22
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
IFRX InflaRx	42.39%
SABS SAB Biotherapeutics	7.82%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
IFRX InflaRx	16.30%
SABS SAB Biotherapeutics	7.39%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Not Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A

ACRV, SABS, UPB, and IFRX Headlines

Recent News About These Companies

Squarepoint Ops LLC Buys 246,278 Shares of Upstream Bio, Inc. $UPB

September 15 at 4:00 AM | marketbeat.com

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

HC Wainwright Forecasts Reduced Earnings for Upstream Bio

September 6, 2026 | americanbankingnews.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, SABS, UPB, and IFRX Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.70 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.06 (+3.82%)

As of 07:30 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

InflaRx NASDAQ:IFRX

$2.06 +0.02 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 +0.04 (+1.94%)

As of 07:57 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

SAB Biotherapeutics NASDAQ:SABS

$3.50 +0.11 (+3.24%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 +0.02 (+0.43%)

As of 07:30 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Upstream Bio NASDAQ:UPB

$5.31 -0.02 (-0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$5.32 +0.01 (+0.19%)

As of 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, SABS, UPB, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, SABS, UPB, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, SABS, UPB, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, SABS, UPB, and IFRX Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

InflaRx NASDAQ:IFRX

SAB Biotherapeutics NASDAQ:SABS

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, SABS, UPB, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, SABS, UPB, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, SABS, UPB, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, SABS, UPB, and IFRX Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

InflaRx NASDAQ:IFRX

SAB Biotherapeutics NASDAQ:SABS

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools